Market revenue in 2023 | USD 20.6 million |
Market revenue in 2030 | USD 70.4 million |
Growth rate | 19.2% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 60.19% in 2023. Horizon Databook has segmented the Latin America plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The rising popularity of gene therapy, rapid growth in the biopharmaceutical industry, and high investments on technology & innovations are the key factors driving growth of plasmid DNA contract manufacturing market in the region.
Increase in the frequency of HIV, cancer, and other incurable diseases is a major driver of gene therapy in the region. In addition, it is anticipated that the market for gene therapy would grow significantly due to the rising prevalence of target diseases and the demand for innovative drugs.
The gene therapy market has grown as a result of ongoing investments and consolidation in cell & gene therapy. Around 16 of the top 20 biopharmaceutical companies in terms of sales added gene therapy items to their portfolios after realizing the market's potential.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America plasmid dna contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account